HCPLive Network

Diabetic Retinopathy Severity Linked to Cardiovascular Outcome

 
THURSDAY, Jan. 24 (HealthDay News) -- For individuals with type 2 diabetes, incident cardiovascular outcomes are determined not only by the severity of diabetic retinopathy but also by its progression, according to research published online Dec. 13 in Diabetes Care.

Hertzel C. Gerstein, M.D., of McMaster University in Hamilton, Canada, and colleagues examined the correlation between retinopathy, four-year progression, and cardiovascular outcomes (cardiovascular death, nonfatal myocardial infarction, or stroke) using data from 3,433 participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and ACCORD Eye Study, who had baseline retinal photographs.

The researchers found that the adjusted hazard ratio for cardiovascular outcome increased from 1.49 for mild retinopathy to 2.35 for severe retinopathy, compared with no retinopathy. For a subset of 2,856 participants evaluated for disease progression at four years, for each category of change in retinopathy severity, the risk of the primary outcome increased by 38 percent. The correlation between progression and cardiovascular outcomes was no longer significant after adjustment for the baseline and follow-up levels of glycated hemoglobin, systolic blood pressure, and lipids either individually or together.

"The clear link between progression of retinal disease and cardiovascular disease suggests that these two serious consequences of diabetes may share an underlying pathophysiological basis," the authors write.
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
Atherosclerotic internal carotid artery disease is a major contributor to ischemic stroke. Surgeons use a combination of carotid artery and brain imaging to determine if patients have symptomatic carotid stenosis. However, there remains widespread disagreement on the threshold, timing, and best technical approach to carotid revascularization in symptomatic patients.
The FDA has cleared a blood test that can screen patients, especially black women, for coronary heart disease.
The US Food and Drug Administration has announced the approval of a new combination treatment for hepatitis C virus.
More Reading